Alyeska Investment Group L.P. Makes New Investment in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,947,369 shares of the company's stock, valued at approximately $1,984,000. Alyeska Investment Group L.P. owned 1.79% of Lineage Cell Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jane Street Group LLC increased its holdings in shares of Lineage Cell Therapeutics by 119.2% during the 4th quarter. Jane Street Group LLC now owns 262,866 shares of the company's stock worth $132,000 after purchasing an additional 142,965 shares during the period. Raffles Associates LP increased its stake in Lineage Cell Therapeutics by 21.8% during the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company's stock valued at $2,760,000 after acquiring an additional 984,307 shares during the period. Comerica Bank raised its holdings in Lineage Cell Therapeutics by 220.0% in the 4th quarter. Comerica Bank now owns 800,000 shares of the company's stock valued at $402,000 after acquiring an additional 550,000 shares in the last quarter. Barclays PLC lifted its position in shares of Lineage Cell Therapeutics by 10.8% in the 4th quarter. Barclays PLC now owns 234,069 shares of the company's stock worth $118,000 after acquiring an additional 22,769 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Lineage Cell Therapeutics by 1,058.3% in the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock worth $1,147,000 after acquiring an additional 2,085,972 shares during the period. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX traded up $0.02 on Monday, reaching $0.46. The company's stock had a trading volume of 194,482 shares, compared to its average volume of 1,307,510. Lineage Cell Therapeutics, Inc. has a 1-year low of $0.37 and a 1-year high of $1.17. The business's 50-day moving average price is $0.47 and its two-hundred day moving average price is $0.63. The firm has a market cap of $101.39 million, a PE ratio of -3.83 and a beta of 1.21.

Wall Street Analyst Weigh In

LCTX has been the subject of a number of analyst reports. B. Riley cut their price target on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, March 14th. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $4.20.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.